




RealRate

PHARMACEUTICAL 2022

Spero Therapeutics Inc
Rank 326 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Spero Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Spero Therapeutics Inc compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 21% points. The greatest weakness of Spero Therapeutics Inc is the variable Other Liabilities, reducing the Economic Capital Ratio by 80% points.

The company's Economic Capital Ratio, given in the ranking table, is 215%, being 60% points below the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	157,872
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	18,670
Liabilities, Non-Current	5,973
Other Assets	12,174
Other Compr. Net Income	5.0
Other Expenses	0
Other Liabilities	58,140
Other Net Income	-1,785
Other Revenues	18,256
Property and Equipment	1,026
Research and Development	64,526
Selling, General and Administrative Expense	41,701

Output Variable	Value in 1000 USD
Assets	171,072
Liabilities	82,783
Expenses	106,227
Revenues	18,256
Stockholders Equity	88,289
Net Income	-89,756
Comprehensive Net Income	-89,754
BaseVar	190,064
ECR before Limited Liability	81%
Economic Capital Ratio	215%